Cardiovascular Systems Stock Current Valuation
Valuation analysis of Cardiovascular Systems helps investors to measure Cardiovascular Systems' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Cardiovascular Systems Company Current Valuation Analysis
Cardiovascular Systems' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cardiovascular Systems Current Valuation | 466.13 M |
Most of Cardiovascular Systems' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiovascular Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Cardiovascular Systems has a Current Valuation of 466.13 M. This is 96.75% lower than that of the Health Care Equipment & Supplies sector and 96.25% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.2% higher than that of the company.
Cardiovascular Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiovascular Systems' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiovascular Systems could also be used in its relative valuation, which is a method of valuing Cardiovascular Systems by comparing valuation metrics of similar companies.Cardiovascular Systems is currently under evaluation in current valuation category among its peers.
Cardiovascular Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0756 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | (0.16) % | |||
| Current Valuation | 466.13 M | |||
| Shares Outstanding | 42.2 M | |||
| Shares Owned By Insiders | 3.22 % | |||
| Shares Owned By Institutions | 89.64 % | |||
| Number Of Shares Shorted | 1.74 M | |||
| Price To Earning | 724.24 X | |||
| Price To Book | 2.43 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 236.22 M | |||
| Gross Profit | 172.78 M | |||
| EBITDA | (29.96 M) | |||
| Net Income | (36.93 M) | |||
| Cash And Equivalents | 159.83 M | |||
| Cash Per Share | 3.90 X | |||
| Total Debt | 22.15 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 6.05 X | |||
| Book Value Per Share | 5.70 X | |||
| Cash Flow From Operations | (24.27 M) | |||
| Short Ratio | 2.66 X | |||
| Earnings Per Share | (0.96) X | |||
| Price To Earnings To Growth | 177.27 X | |||
| Target Price | 16.75 | |||
| Number Of Employees | 725 | |||
| Beta | 0.74 | |||
| Market Capitalization | 843.96 M | |||
| Total Asset | 322.68 M | |||
| Retained Earnings | (320 M) | |||
| Working Capital | 69.38 M | |||
| Current Asset | 104.88 M | |||
| Current Liabilities | 35.5 M | |||
| Z Score | 22.8 | |||
| Net Asset | 322.68 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Cardiovascular Stock
If you are still planning to invest in Cardiovascular Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cardiovascular Systems' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |